Evidence map›Paper›PMID 38321299›Full record

ArticleJournal of molecular modeling2024

Evaluation of the inhibitory potential of bioactive compounds against SARS-CoV-2 by in silico approach.

J Mariya Sneha Rani, P Akkarshana, V Neelaveni, Shalini Mohan, P D Rekha, Rajas M Rao, Lakshmanan Muthulakshmi

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Gallic Acid fromAntioxidants (Basel, Switzerland) · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

J Mariya Sneha RaniDepartment of Biotechnology, Biomaterials and Product Development Laboratory, Kalasalingam Academy of Research and Education, Krishnankoil, 626126, India.
P AkkarshanaDepartment of Biotechnology, Biomaterials and Product Development Laboratory, Kalasalingam Academy of Research and Education, Krishnankoil, 626126, India.
V NeelaveniDepartment of Biotechnology, Biomaterials and Product Development Laboratory, Kalasalingam Academy of Research and Education, Krishnankoil, 626126, India.
Shalini MohanDepartment of Biotechnology, Biomaterials and Product Development Laboratory, Kalasalingam Academy of Research and Education, Krishnankoil, 626126, India.
P D RekhaYenepoya Research Centre, Yenepoya (Deemed to Be University), Mangaluru, 575018, India.
Rajas M RaoYenepoya Research Centre, Yenepoya (Deemed to Be University), Mangaluru, 575018, India. rajasmr@yenepoya.edu.in.
Lakshmanan MuthulakshmiDepartment of Biotechnology, Biomaterials and Product Development Laboratory, Kalasalingam Academy of Research and Education, Krishnankoil, 626126, India. l.muthulakshmi@klu.ac.in.
Kalasalingam Academy of Research and Education · INYenepoya University · IN

Funding

Department of Biotechnology, Ministry of Science and Technology, India DBT/2022-23/KARE/2059Department of Scientific and Industrial Research, Ministry of Science and Technology, India (Ref.No.F.No.TDUPW-1 1011/3/2021-IRD (SC)DSIR)Kalsalingam Academy of Research and Education KARE Seed Money Grant
6 · The paper itself

Abstract

contextThe COVID-19 (coronavirus disease 19) pandemic brought on by the SARS-CoV-2 outbreak (severe acute respiratory syndrome coronavirus 2) has stimulated the exploration of various available chemical compounds that could be used to treat the infection. This has driven numerous researchers to investigate the antiviral potential of several bioactive compounds from medicinal plants due to their reduced adverse effects compared to chemicals. Some of the bioactive compounds used in folklore treatment strategies are reported as effective inhibitors against the proliferative and infective cycles of SARS-CoV-2. The secondary metabolites from plants are generally used to treat various diseases due to their intact medicinal properties. The present study analyzes the inhibitory potential of phytochemicals from medicinal plants like Sphaeranthus indicus, Lantana camara, and Nelumbo nucifera against SARS-CoV-2 by molecular docking.

methodsTen druggable protein targets from SARS-CoV-2 are docked against the phytochemicals from the selected medicinal plants. The phytocompounds astragalin, isoquercetin, and 5-hydroxy-7-methoxy-6-c-glycosy flavone were found to have lower binding energy depicting their inhibitive potential compared with the reported inhibitors that are used in the treatment of SARS-CoV-2 infection. The phytocompounds found to have the least binding energy were selected for further analyses. To assess the compounds' potential as drugs, their ADMET characteristics were also examined. Sphaeranthus indicus, Lantana camara, and Nelumbo nucifera six possible compounds were separately screened for ADME and toxicity characteristics; then, the results were analyzed. To assess the impact of the phytocompound binding on the dynamics of SARS-CoV-2 ribonuclease protein NSP15, microsecond-level all atomistic molecular dynamics simulations were performed, and their dynamics were analyzed. Microsecond-level molecular dynamics simulations of both the ligands complexed with NSP15 revealed that the ligand induces allosteric effects on NSP15, which could lead to destabilization of NSP15 hexameric interface and loss of RNA binding. The low binding energy exhibited by the phytochemicals from Lantana camera, Sphaeranthus indicus, and Nelumbo nucifera against the protein targets of SARS-CoV-2 showed inhibitory potential by the selected molecules. Their predicted interference of the enzymes involved in the molecular mechanisms aiding the proliferation of SARS-CoV-2 indicated the inhibitive ability of the phytochemicals.

Indexed as

COVID-19SARS-CoV-2Antiviral AgentsHumansMolecular Docking SimulationMolecular Dynamics SimulationAntiviral AgentsAntiviral compoundsInhibitorsLipinski’s rule of fiveMolecular dockingMolecular dynamic simulationPhytochemicalsSARS-CoV-2SwissADME

Identifiers

PMID38321299
OpenAlexW4391738096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.